According to some studies, hospitalizations from all causes of pneumonia declined in 18-39 year old adults in the U.S. by 26% 4 years after PCV7 vaccine was included in the infant vaccination schedule and by a further 12% with the first 2 years after PCV13 replaced PCV7. Though reductions in older age groups were not statistically significant, other U.S. studies showed significant reductions in pneumonia hospitalization rates in all adult age groups, including the elderly.
Full Citation:
Wiese AD, Griffin MR, Grijalva CG. 2019. Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Review of Vaccines. 18(4).
Title of Article: Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States
Author(s): Wiese AD, Griffin MR, Grijalva CG
Publication Year: 2019
Publication Name: Expert Review of Vaccines
Publication Volume: 18(4)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pubmed/30759352
DOI (Digital Object Identifier): 10.1080/14760584.2019.1582337
Topics: Health System Strengthening
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: United States
WHO Regions: Americas